Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. - Wikidata - awgldk - TriplyDB

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

http://www.wikidata.org/entity/Q44931488

about

Effects of nilotinib on regulatory T cells: the dose matters The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.Libraries of 2β-(N-substituted piperazino)-5α-androstane-3α, 17β-diols: chemical synthesis and cytotoxic effects on human leukemia HL-60 cells and on normal lymphocytes.The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy Platelet-derived growth factor, transforming growth factor-beta, and connective tissue growth factor in a porcine bronchial model of obliterative bronchiolitis.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection.Hepatitis B reactivation in patients receiving targeted therapies.Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan.Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease.Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.Lck is a key target of imatinib and dasatinib in T-cell activation.Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML.Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.Therapeutics in renal disease: the road ahead for antiproliferative targets.

P2860

Q21245709-7E9C1A33-9CDE-48BA-9B4D-97771E7B168F Q30482430-2247BF8F-9025-4168-8958-A653D628C82C Q33644438-CBCC59E6-6804-4FC5-940E-9F333490FBBA Q33688172-8B761FA6-2846-4628-A4A4-9984CEAC31B3 Q34015801-58E06416-8956-40AA-B6D6-BFAD9D324E3B Q35608944-59C8BFE5-5D3D-44F9-B0DD-B4B545A86712 Q35739389-9C412EC9-96B2-4E1A-87C8-604751F6D553 Q36110355-BDAD6A8A-7188-4D3B-B8BF-FDD1AC70FE5D Q36220062-EE1E3995-9AF1-4E7E-8309-C41A51C5B54A Q36407079-C54F034B-92D0-46BB-B5A2-FF95FE8E4C93 Q36654518-FC6D7A40-3242-4782-BDF9-A0A60632253B Q37326191-568AD81E-8C71-4720-A07C-760720BC4D5B Q37541654-8EA9B8B8-6464-4098-965F-4AF882BBCB06 Q37702242-187B3A75-1817-4937-AAB4-76A708E76F46 Q37842326-1FE99A8A-6C2B-4083-99B0-481BC60EB6B3 Q38261946-C2539C27-9C0B-48B6-AC80-0CE080BF4672 Q38299218-2061C874-CB8A-4588-B9D4-1FB1B7E862E0 Q38810735-5A11A289-93D2-40FE-A7E1-DF8029CE9A8C Q39226064-07183495-FF08-4862-8D8D-F2E143038B0B Q39293427-BAF8A68D-77CA-4A27-8452-961753C396C9 Q41356321-57D673AA-7688-42C8-B97F-4407C5ADE94B Q41744560-4A7C39C9-33F2-4583-B97B-BDA5F9785160 Q41963473-20B806B4-E601-4F2E-AB72-9120B01C132C Q42015762-F466CA04-18D0-4919-889F-0CA77A8E890E Q42258804-441B3BC3-F7C1-46B5-A9B3-6406EBEA6C6D Q42276725-2F2F6105-3A1A-4CFC-BC09-626108C85D2F Q43165902-0A8BDE24-BAB1-4B63-A035-86A86B340A6D Q45240579-EDFAFAB6-0C93-4E10-A145-E11059BF367C Q45422025-F33773D4-787C-4624-9DDE-FACEE2C82E75 Q45949146-EF41C9E9-F8D1-4232-9D5E-44DE84D7ED71 Q46693880-09114A46-39EF-4933-ACA9-A76F7D032764 Q46736545-2526AE78-3278-4B1C-8984-DF5A22BE76D1 Q46799041-992F0615-57AD-44DE-AF02-4A09069EF272 Q46819252-69A403B4-DF7B-428B-85BA-34425D527DF2 Q47113340-3135CF02-4974-452B-A5DC-89CDADBAA5F8 Q47350013-04CF1EB9-2969-416E-8190-5461F2A5D7D1 Q49291505-05CAD417-6408-4B0E-9858-A31E20C34890 Q53215863-5F1A7902-24BC-420D-A1F9-CF79EE168FE6 Q53280145-C2A40140-D118-4EE6-BFF6-8F69AC526C41 Q53644742-387998A2-E9A5-4626-9A65-721DE4FEDE20

P2860

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

http://www.wikidata.org/entity/Q44931488

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@en

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@nl

type

label

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@en

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@nl

prefLabel

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@en

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@nl

P1433

Q44931488-3BADF73B-3A27-4B6E-BF81-DDEA88292D3F

P1476

Q44931488-09919475-4865-4AD4-828C-C8C375831AB9

P2093

Q44931488-44C0D3AD-705B-47CF-9D00-F6AEACCB5386

Q44931488-70394BB3-5D79-4D8A-8282-EDEF2032CD2A

Q44931488-7A14CEB4-6B1B-486D-A0DB-3DB894DEE433

Q44931488-C1C67AEC-63FD-49B7-81F4-94CD4A13EB4E

Q44931488-CD7D5170-A14E-4461-B0E3-48DF853C0435

Q44931488-F5960E49-9854-4BDC-B067-E07180E5DB9A

Q44931488-FBFD77B1-FF1F-41D4-BE4B-958C2CB3D3DD

P2860

Q44931488-103AEA7C-C4F3-4D25-B3E2-3FA7B2154E5E

Q44931488-130B3C2E-1020-4681-BAE4-1A35F6D69F44

Q44931488-1C7EE991-5D52-4F22-9645-45B1993F6599

Q44931488-1DEC3F16-0807-4570-92FC-F029E1A55BAD

Q44931488-1DF86D3E-6ADD-492C-A9BE-88FE822C6196

Q44931488-1EC605F0-0587-4468-98F8-9A1895126C62

Q44931488-261EE616-AF16-4082-9DAB-68DD26F3FDBA

Q44931488-2D672F48-1FB6-4AD6-9EA5-181B1B0A4565

Q44931488-34C85E4A-1D4C-4FFA-8472-E32D77E8F18A

Q44931488-35A99A93-F94D-46FE-A9F8-8A982118F8C7

P2888

Q44931488-CC79C00B-6E50-4DD3-8125-D9751D7C18C8

P304

Q44931488-B27D4427-58FC-4FE6-8B6A-212D013E1947

P31

Q44931488-DEAF9B46-EA99-4BA7-85C1-0282C9050745

P356

Q44931488-391ECA4E-B4B1-4FDC-8427-A2ED42C49812

P433

Q44931488-4EC23465-8478-40C2-9A11-1A30A6A3EFC1

P478

Q44931488-3CA22037-70C6-4006-ACB8-2DE761BE7537

P577

Q44931488-7C508320-1DBD-4B28-9F69-E244057B81B2

P5875

Q44931488-19226D89-8932-42C7-A27E-760B3D3CDD6A

P6179

Q44931488-2F9CCC91-228D-4DF3-9F9A-0393C91B098D

P698

Q44931488-ADD0E9DC-D84B-449D-AAA7-C7E2AD735A81

P356

P1433

P1476

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.

@en

P2093

Cwynarski K

http://www.w3.org/2001/XMLSchema#string

Dazzi F

http://www.w3.org/2001/XMLSchema#string

Goldman J

http://www.w3.org/2001/XMLSchema#string

Laylor R

http://www.w3.org/2001/XMLSchema#string

Lombardi G

http://www.w3.org/2001/XMLSchema#string

Macchiarulo E

http://www.w3.org/2001/XMLSchema#string

Melo JV

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-10 and the interleukin-10 receptor

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo.

ARG tyrosine kinase activity is inhibited by STI571.

P2888

P304

1332-1339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2403401

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8517571

http://www.w3.org/2001/XMLSchema#string

P6179

1021101569

http://www.w3.org/2001/XMLSchema#string

P698

15190258

http://www.w3.org/2001/XMLSchema#string